cAMP signaling comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-14. Numbers and descriptions here follow the published literature rather than marketing material.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
=== United States === As of July 2012, only six states lack legislation to regulate the professional practice of TCM: Alabama, Kansas, North Dakota, South Dakota, Oklahoma, and Wyoming. In 1976, California established an Acupuncture Board and became the first state licensing professional acupuncturists.
In the late 6th century, following Justinian I's wars, seven mobile field armies called comitatenses, numbering around 150,000 troops, were deployed around the empire; they remained the finest armies in Europe. They were aided by twenty-five frontier garrisons of approximately 195,000 lower-quality limitanei troops. Additional troops included subsidised allied forces and imperial guard units like the Scholae Palatinae. Naval forces were limited: flotillas were based at key locations, while 30,000 oarsmen were assembled to row 500, mostly requisitioned, transports to support the Vandalic War in Africa in 533. The losses suffered in the 7th-century Arab conquests led to fundamental changes. The field armies were withdrawn into the core Anatolian territories and assigned to settle in specific districts, which became known as themata and eventually replaced the old provinces. The thematic armies, supported by the proceeds of their districts, came to resemble a provincial militia with a small professional core, aided by foreign mercenaries and imperial regiments at Constantinople. To defend against its new Muslim enemy, the navy was similarly reorganised into several provincialised fleets. It became the dominant power in the eastern Mediterranean, with dromons equipped with Greek fire proving crucial on several occasions. As the 8th-century empire stabilised, the thematic militias proved rebellious and only suitable for defensive operations.
=== Other cultures === Scorpions are among the many animals modelled in the art of the Moche culture of Peru. Mimbres artists in the south of New Mexico created painted ceramics of scorpions and many other symbolic and mythological animals on funerary bowls. A hole was ritually punched through the bottom of the bowl to "kill" it during a funeral.
=== Rabbits and goats === In 2016, the CRISPR/Cas9 system was used to genetically engineer rabbits and goats with no functional copies of the myostatin gene. In both cases the resulting animals were significantly more muscular. However, rabbits without myostatin also exhibited an enlarged tongue, a higher rate of still births, and a reduced lifespan.
Allyl alcohol (IUPAC name: prop-2-en-1-ol) is an organic compound with the structural formula CH2=CHCH2OH. Like many alcohols, it is a water-soluble, colourless liquid. It is more toxic than typical small alcohols. Allyl alcohol is used as a precursor to many specialized compounds such as flame-resistant materials, drying oils, and plasticizers. Allyl alcohol is the smallest representative of the allylic alcohols.
Sources: en.wikipedia.org
== Treatment == The primary treatment for urethral diverticulum is surgical. In women, the surgery is conducted transvaginally, usually when there is no acute inflammation to better aid dissection of the delicate tissues.
=== Renaming === The laboratory was renamed Lawrence Livermore Laboratory (LLL) in 1971. On October 1, 2007 Lawrence Livermore National Security, LLC (LLNS) assumed management of LLNL from the University of California, which had exclusively managed and operated the Laboratory since its inception 55 years before. The laboratory was honored in 2012 by having the synthetic chemical element livermorium named after it. The LLNS takeover of the laboratory has been controversial. In May 2013, an Alameda County jury awarded over $2.7 million to five former laboratory employees who were among 430 employees LLNS laid off during 2008. The jury found that LLNS breached a contractual obligation to terminate the employees only for "reasonable cause." The five plaintiffs also have pending age discrimination claims against LLNS, which will be heard by a different jury in a separate trial. There are 125 co-plaintiffs awaiting trial on similar claims against LLNS. The May 2008 layoff was the first layoff at the laboratory in nearly 40 years. On March 14, 2011, the City of Livermore officially expanded the city's boundaries to annex LLNL and move it within the city limits. The unanimous vote by the Livermore city council expanded Livermore's southeastern boundaries to cover 15 land parcels covering 1,057 acres (4.28 km2) that comprise the LLNL site. The site was formerly an unincorporated area of Alameda County. The LLNL campus continues to be owned by the federal government.
ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing) is a laboratory technique used in molecular biology to assess genome-wide chromatin accessibility. The technique was introduced in 2013 by the labs of Will Greenleaf and Howard Chang at Stanford University as an alternative to MNase-seq, FAIRE-Seq and DNase-Seq with faster turnaround time, simpler protocol, and lower DNA input requirements.
==== Example: half-life of Rb-87 ==== One gram of rubidium-87 and a radioactivity count rate that, after taking solid angle effects into account, is consistent with a decay rate of 3200 decays per second corresponds to a specific activity of 3.2×106 Bq/kg. Rubidium atomic mass is 87 g mol−1, so one gram is 1/87 of a mole. Plugging in the numbers:
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.